European Lung Cancer Congress 2022

Search results (14)

Lung and other thoracic tumours

30 Mar 2022

Patient-reported outcomes favour first-line three-drug combination in metastatic NSCLC

Read more

Heine H. Hansen Award 2022

30 Mar 2022

Fred R. Hirsch receives the Heine H. Hansen Award 2022

Read more

16 Feb 2022

European Lung Cancer Congress 2022: Prof. Lizza Hendriks tells you why you can’t miss this event

Watch video

Lung and other thoracic tumours

31 Mar 2022

Assessing pathological response after neoadjuvant treatment for NSCLC

Much progress has been made in the standardisation of pathological response but optimising viable tumour cutoffs for predicting long-term outcome after different treatment modalities and by histological type remain key areas for investigation 

By William Travis

Read more

Lung and other thoracic tumours

31 Mar 2022

Results for two new third-generation EGFR tyrosine kinase inhibitors do not suggest advantages over osimertinib

Read more

Cancer Immunology and Immunotherapy

31 Mar 2022

Atezolizumab shows little heterogeneity in efficacy in high PD-L1 expressers with stage II–IIIA NSCLC

Read more

European Lung Cancer Congress 2022

30 Mar 2022

Patient-reported outcomes are essential when their availability is prompt

By
• Massimo Di Maio - Guest editor

Read more

Cancer Immunology and Immunotherapy

31 Mar 2022

Encouraging safety data for the use of durvalumab after sequential chemotherapy in stage III unresectable NSCLC

Read more

Lung and other thoracic tumours

31 Mar 2022

Perioperative survival after bilobectomy is worse than lobectomy

Read more

Lung and other thoracic tumours

30 Mar 2022

How can we continue to improve outcomes for our patients with lung cancer?

Advances made in the treatment of advanced lung cancer are now being introduced at earlier stages of disease  

By Pasi A. Jänne

Read more